Synthesis of a C-terminally biotinylated macrocyclic peptide mimetic exhibiting high Grb2 SH2 domain-binding affinity

被引:14
作者
Shi, ZD
Liu, HP
Zhang, MC
Worthy, KM
Bindu, L
Yang, DJ
Fisher, RJ
Burke, TR [1 ]
机构
[1] NCI, CCR, Med Chem Lab, NIH, Frederick, MD 21702 USA
[2] Univ Michigan, Sch Med, Ann Arbor, MI 48109 USA
[3] SAIC Frederick, Prot Chem Lab, Frederick, MD 21702 USA
关键词
D O I
10.1016/j.bmc.2005.04.028
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although considerable effort has been devoted to developing Grb2 SH2 domain-binding antagonists, important questions related to ligand specificity, and identification of intracellular targets remain unanswered. In order to begin addressing these issues, the design, synthesis, and evaluation of a novel biotinylated macrocycle are reported that bears biotin functionality at a C-terminal rather than the traditional N-terminal position. With a Grb2 SH2 domain-binding K-eq value of 3.4 nM, the title macrocycle (5) is among the most potent biotinylated SH2 domain-binding ligands yet disclosed. This should be a useful tool for elucidating physiological targets of certain Grb2 SH2 domain-binding antagonists. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4200 / 4208
页数:9
相关论文
共 30 条
  • [1] Potent blockade of hepatocyte growth factor-stimulated cell motility, matrix invasion and branching morphogenesis by antagonists of Grb2 Src homology 2 domain interactions
    Atabey, N
    Gao, Y
    Yao, ZJ
    Breckenridge, D
    Soon, L
    Soriano, JV
    Burke, TR
    Bottaro, DP
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (17) : 14308 - 14314
  • [2] Biotinylated geldanamycin
    Clevenger, RC
    Raibel, JM
    Peck, AM
    Blagg, BSJ
    [J]. JOURNAL OF ORGANIC CHEMISTRY, 2004, 69 (13) : 4375 - 4380
  • [3] DALY RJ, 1994, ONCOGENE, V9, P2723
  • [4] Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: Implications for human breast cancer
    Dankort, D
    Maslikowski, B
    Warner, N
    Kanno, N
    Kim, H
    Wang, ZX
    Moran, MF
    Oshima, RG
    Cardiff, RD
    Muller, WJ
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2001, 21 (05) : 1540 - 1551
  • [5] High affinity molecules disrupting GRB2 protein complexes as a therapeutic strategy for chronic myelogenous leukaemia
    Feller, SM
    Tuchscherer, G
    Voss, J
    [J]. LEUKEMIA & LYMPHOMA, 2003, 44 (03) : 411 - 427
  • [6] Structure-based design of compounds inhibiting Grb2-SH2 mediated protein-protein interactions in signal transduction pathways
    Fretz, H
    Furet, P
    García-Echeverría, C
    Rahuel, J
    Schoepfer, J
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2000, 6 (18) : 1777 - 1796
  • [7] Structure-based design and synthesis of nigh affinity tripeptide ligands of the Grb2-SH2 domain
    Furet, P
    Gay, B
    Caravatti, G
    García-Echeverría, C
    Rahuel, J
    Schoepfer, J
    Fretz, H
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1998, 41 (18) : 3442 - 3449
  • [8] Olefin metathesis in the design and synthesis of a globally constrained Grb2 SH2 domain inhibitor
    Gao, Y
    Wei, CQ
    Burke, TR
    [J]. ORGANIC LETTERS, 2001, 3 (11) : 1617 - 1620
  • [9] Inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. 2. 4-(2-malollyl)phenylalanine as a potent phosphotyrosyl mimetic
    Gao, Y
    Luo, J
    Yao, ZJ
    Guo, RB
    Zou, H
    Kelley, J
    Voigt, JH
    Yang, DJ
    Burke, TR
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (05) : 911 - 920
  • [10] Inhibitors of RAS signal transduction as antitumor agents
    Garbay, C
    Liu, WQ
    Vidal, M
    Rogues, BP
    [J]. BIOCHEMICAL PHARMACOLOGY, 2000, 60 (08) : 1165 - 1169